首页> 外文期刊>Experimental and clinical transplantation >Use of Monitoring Gamma-Glutamyl Transpeptidase Levels After Liver Transplant: A Longitudinal Retrospective Analysis of a Single-Center’s Experience
【24h】

Use of Monitoring Gamma-Glutamyl Transpeptidase Levels After Liver Transplant: A Longitudinal Retrospective Analysis of a Single-Center’s Experience

机译:监测肝移植后γ-谷氨酰转肽酶的水平:单中心经验的纵向回顾性分析

获取原文
           

摘要

Objectives: Recently, gamma-glutamyl transpeptidase has garnered increased attention as a diagnostic tool in the early identification of liver disease. However, its value in liver transplant is largely unknown, as the disease processes leading to abnormal gamma-glutamyl transpeptidase levels and the expected temporal trends in gamma-glutamyl transpeptidase levels during the period after liver transplant remain unclear. Materials and Methods: Between January 2010 and August 2013, consecutive patients who underwent liver transplant at Vancouver General Hospital (Vancouver, Canada) were assessed longitudinally up to 1 year after liver transplant. A “gamma-glutamyl transpeptidase event” was defined as 2 abnormal gamma-glutamyl transpeptidase values (exceeding sex-specific limits of normal, at 55 U/L for female and 80 U/L for male patients) ≥ 1 week apart . Results: Our study included 147 liver transplant recipients. The median gamma-glutamyl transpeptidase level on day 1 after liver transplant was 73 U/L, which peaked to 435 U/L during the first month after liver transplant and returned to within normal parameters by 1 year. In total, there were 282 gamma-glutamyl transpeptidase events, with biliary complications (22%), acute rejection (16%), and hepatitis C virus recurrence (10%) being the most common causes. In 39% of events, no cause was identified. When attempting to identify a disease-associated event, if gamma-glutamyl transpeptidase was the initial liver biochemistry test to double in value, it had 42% sensitivity and 40% specificity. Comparatively, if gamma-glutamyl transpeptidase was the initial liver biochemistry test to become abnormal, it had 3% sensitivity and 93% specificity. Conclusions: Although gamma-glutamyl transpeptidase almost universally becomes abnormal after liver transplant, a specific pathologic cause was not commonly identified. Interpreting the characteristics of gamma-glutamyl transpeptidase elevation has limited use for identifying the underlying reason for its elevation.
机译:目的:近来,γ-谷氨酰转肽酶作为肝病早期诊断的诊断工具受到越来越多的关注。但是,其在肝移植中的价值在很大程度上是未知的,因为导致肝移植后的γ-谷氨酰转肽酶水平异常的疾病进程以及γ-谷氨酰转肽酶水平的预期时间趋势仍不清楚。材料和方法:在2010年1月至2013年8月之间,对在温哥华总医院(加拿大温哥华)进行肝移植的连续患者进行了肝移植后长达1年的纵向评估。 “γ-谷氨酰转肽酶事件”定义为相距≥1周的2个异常的γ-谷氨酰转肽酶值(超过正常的性别特异性极限,女性为55 U / L,男性为80 U / L)。结果:我们的研究包括147位肝移植受者。肝移植后第1天的中位γ-谷氨酰转肽酶水平为73 U / L,在肝移植后的第一个月达到435 U / L,并在1年内恢复正常。总共有282次γ-谷氨酰转肽酶事件,其中最常见的原因是胆道并发症(22%),急性排斥反应(16%)和丙型肝炎病毒复发(10%)。在39%的事件中,未找到原因。当试图确定与疾病相关的事件时,如果最初的肝脏生物化学测试将γ-谷氨酰转肽酶的价值提高一倍,则它具有42%的敏感性和40%的特异性。相比较而言,如果最初的肝脏生化测试发现γ-谷氨酰转肽酶异常,则其敏感性为3%,特异性为93%。结论:尽管在肝移植后γ-谷氨酰转肽酶几乎普遍变得异常,但通常并未确定具体的病理原因。解释γ-谷氨酰转肽酶升高的特征在确定其升高的根本原因方面用途有限。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号